Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype (Q42986419)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2013

Language	Label	Description	Also known as
English	Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype	scientific article published on March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

Norio Itokawa

1

1 reference

Europe PubMed Central

12 November 2017

Masanori Atsukawa

2

1 reference

Europe PubMed Central

12 November 2017

Akihito Tsubota

3

1 reference

Europe PubMed Central

12 November 2017

Chisa Kondo

4

1 reference

Europe PubMed Central

12 November 2017

Satomi Hashimoto

5

1 reference

Europe PubMed Central

12 November 2017

Takeshi Fukuda

6

1 reference

Europe PubMed Central

12 November 2017

Yoko Matsushita

7

1 reference

Europe PubMed Central

12 November 2017

Hideko Kidokoro

8

1 reference

Europe PubMed Central

12 November 2017

Tamaki Kobayashi

9

1 reference

Europe PubMed Central

12 November 2017

Yoshiyuki Narahara

10

1 reference

Europe PubMed Central

12 November 2017

Katsuhisa Nakatsuka

11

1 reference

Europe PubMed Central

12 November 2017

Hidenori Kanazawa

12

1 reference

Europe PubMed Central

12 November 2017

Katsuhiko Iwakiri

13

1 reference

Europe PubMed Central

12 November 2017

Choitsu Sakamoto

14

1 reference

Europe PubMed Central

12 November 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

12 November 2017

28

1 reference

Europe PubMed Central

12 November 2017

3

1 reference

Europe PubMed Central

12 November 2017

443-449

1 reference

Europe PubMed Central

12 November 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Antiviral therapy for chronic hepatitis C: past, present, and future

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

New therapeutic approaches to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Identifiers

10.1111/JGH.12039

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42986419&oldid=1975875784"